NovaBay Pharmaceuticals, Inc. (NYSE: NBY)

NovaBay Pharmaceuticals, Inc. (NBY) operates in the healthcare industry, specializing in the development and sale of scientifically-created and clinically-proven eyecare and wound care products. The company's main business activities involve designing, manufacturing, and marketing products that cater to the needs of individuals suffering from dry eye disease and blepharitis, a common condition characterized by inflammation and irritation of the eyelids.

NovaBay generates revenue primarily through the sale of its products, including its leading product, Avenova Antimicrobial Lid and Lash Solution, or Avenova Spray. This proprietary form of hypochlorous acid has been shown to neutralize bacterial toxins in laboratory tests. The company's product portfolio also includes Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenoa, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. In the wound care segment, NovaBay offers NeutroPhase and PhaseOne for the cleansing and irrigation of wounds.

The company operates in a competitive industry, facing competition from other companies such as Vashe and Betadine Surgical Scrub. However, NovaBay believes its products have distinct competitive advantages, including their gentle and non-irritating nature, making them suitable for use on sensitive skin and new tissue.

NovaBay's customers include individuals who suffer from dry eye disease and blepharitis, as well as healthcare professionals who prescribe and dispense the company's products. The company's products are also used by hospitals and clinics for wound care and other medical procedures.

In terms of intellectual property, NovaBay owns patents and trademarks for its products, including Avenova Spray and NeutroPhase. The company also relies on trade secrets and know-how to maintain its competitive position.

Currently, NovaBay is not conducting substantial research and development activities. However, the company is committed to ongoing innovation and improvement of its products, and is continually evaluating new technologies and products to add to its portfolio.

NovaBay is subject to regulation by the FDA and other government agencies, and must comply with various laws and regulations, including the Federal Food, Drug and Cosmetic Act and the Public Health Service Act. The company is also subject to anti-kickback laws and false claims laws, which prohibit the payment or receipt of kickbacks, bribes or other remuneration in exchange for the referral of patients or other health-related business.

NovaBay has experienced significant revenue growth in recent years, driven by the success of its Avenova Spray product. However, the company has also experienced significant expenses, including research and development expenses, and has reported net losses in recent years. NovaBay is seeking to address its financial challenges through cost reduction measures and strategic initiatives, including the sale of its DERMAdoctor subsidiary.